热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　君实生物（01877）绩后股价上涨6.28%，现报15.56港元，成交额4982.05万港元。

　　3月27日，君实生物发布截至2024年12月31日止年度的全年业绩，收入19.48亿元（人民币，下同），同比增加29.67%；股东应占亏损12.82亿元，同比收窄43.79%；每股基本亏损1.3元。

　　公告称，收入增加主要由于药品收入的增加，其中：核心产品拓益®（特瑞普利单抗）国内销售收入约为15.01亿元，较2023年同期增加约66%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.